Trajectories of antipsychotic response in drug-naive schizophrenia patients: Results from the 6-month ESPASS follow-up study

Acta Psychiatrica Scandinavica

Volumn 129, Issue 2, 2014, Pages 116-125

  Nordon, C ^a,b   Rouillon, F ^b   Azorin, J M ^c   Barry, C ^a   Urbach, M ^d   Falissard, B ^a,e  

^a Universite Paris Sud   (France)

^b CENTRE HOSPITALIER SAINTE ANNE   (France)

^c HÔPITAL SAINTE MARGUERITE   (France)

^d CENTRE HOSPITALIER DE VERSAILLES   (France)

^e HÔPITAL PAUL BROUSSE   (France)

Author keywords

Antipsychotic agents; Drug response; Heterogeneity; Schizophrenia; Trajectories

Indexed keywords

AMISULPRIDE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ARIPIPRAZOLE; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ADULT; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; DISEASE SEVERITY; DRUG RESPONSE; EMPLOYMENT; FEMALE; FOLLOW UP; FRANCE; HUMAN; INCOME; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEGATIVE SYNDROME; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RELAPSE; SCHIZOPHRENIA; SYMPTOM; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIPSYCHOTIC AGENTS; DRUG RESPONSE; HETEROGENEITY; SCHIZOPHRENIA; TRAJECTORIES;

ADULT; ANTIPSYCHOTIC AGENTS; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LOGISTIC MODELS; MALE; MULTIVARIATE ANALYSIS; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84891824742     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/acps.12135     Document Type: Article

References (48)

1. Robinson DG, Woerner MG, Alvir JM et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 1999;156:544-549.
2. Gasquet I, Haro JM, Novick D, Edgell ET, Kennedy L, Lepine JP. Pharmacological treatment and other predictors of treatment outcomes in previously untreated patients with schizophrenia: results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Int Clin Psychopharmacol 2005;20:199-205.
3. Ucok A, Polat A, Cakir S, Genc A. One year outcome in first episode schizophrenia. Predictors of relapse. Eur Arch Psychiatry Clin Neurosci 2006;256:37-43.
4. Huber CG, Naber D, Lambert M. Incomplete remission and treatment resistance in first-episode psychosis: definition, prevalence and predictors. Expert Opin Pharmacother 2008;9:2027-2038.
5. Whitty P, Clarke M, McTigue O et al. Predictors of outcome in first-episode schizophrenia over the first 4 years of illness. Psychol Med 2008;38:1141-1146.
6. White C, Stirling J, Hopkins R et al. Predictors of 10-year outcome of first-episode psychosis. Psychol Med 2009;39:1447-1456.
7. Simonsen E, Friis S, Opjordsmoen S et al. Early identification of non-remission in first-episode psychosis in a two-year outcome study. Acta Psychiatr Scand 2010;122:375-383.
8. Schennach-Wolff R, Seemuller FH, Mayr A et al. An early improvement threshold to predict response and remission in first-episode schizophrenia. Br J Psychiatry 2010;196:460-466.
9. Nagin DS. Group-Based Modeling of Development. Cambridge, Massachusetts: Harvard University Press, 2005.
10. Pingault JB, Cote SM, Galera C et al. Childhood trajectories of inattention, hyperactivity and oppositional behaviors and prediction of substance abuse/dependence: a 15-year longitudinal population-based study. Mol Psychiatry 2012 [Epub ahead of print].
11. Cole VT, Apud JA, Weinberger DR, Dickinson D. Using latent class growth analysis to form trajectories of premorbid adjustment in schizophrenia. J Abnorm Psychol 2012;121:388-395.
12. Levine SZ, Leucht S. Elaboration on the early-onset hypothesis of antipsychotic drug action: treatment response trajectories. Biol Psychiatry 2010;68:86-92.
13. Case M, Stauffer VL, Ascher-Svanum H et al. The heterogeneity of antipsychotic response in the treatment of schizophrenia. Psychol Med 2011;41:1291-1300.
14. Stauffer V, Case M, Kollack-Walker S et al. Trajectories of response to treatment with atypical antipsychotic medication in patients with schizophrenia pooled from 6 double-blind, randomized clinical trials. Schizophr Res 2011;130:11-19.
15. Schennach R, Meyer S, Seemuller F et al. Response trajectories in "real-world" naturalistically treated schizophrenia patients. Schizophr Res 2012;139:218-224.
16. Levine SZ, Lurie I, Kohn R, Levav I. Trajectories of the course of schizophrenia: from progressive deterioration to amelioration over three decades. Schizophr Res 2011;126:184-191.
17. Levine SZ, Rabinowitz J. Trajectories and antecedents of treatment response over time in early-episode psychosis. Schizophr Bull 2010;36:624-632.
18. Levine SZ, Rabinowitz J, Case M, Ascher-Svanum H. Treatment response trajectories and their antecedents in recent-onset psychosis: a 2-year prospective study. J Clin Psychopharmacol 2010;30:446-449.
19. Limosin F, Gasquet I, Leguay D, Azorin JM, Rouillon F. Body mass index and prevalence of obesity in a French cohort of patients with schizophrenia. Acta Psychiatr Scand 2008;118:19-25.
20. Nordon C, Rouillon F, Barry C, Gasquet I, Falissard B. Determinants of treatment satisfaction of schizophrenia patients: Results from the ESPASS study. Schizophr Res 2012;139:211-217.
21. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders - fourth edition - revised. Washington, DC, USA: American Psychiatric Association, 2000.
22. Tandon R, Devellis RF, Han J et al. Validation of the Investigator's Assessment Questionnaire, a new clinical tool for relative assessment of response to antipsychotics in patients with schizophrenia and schizoaffective disorder. Psychiatry Res 2005;136:211-221.
23. Leguay D, Cochet A, Matignon G, Hairy A, Fortassin O, Marion JM. [Social Autonomy Scale. First validation data]. Encephale 1998;24:108-119.
24. Guy W. CGI: Clinical Global Impressions. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD, USA: Department of Health, Education, and Welfare, 1976.
25. Leucht S, Kane JM, Etschel E, Kissling W, Hamann J, Engel RR. Linking the PANSS, BPRS, and CGI: clinical implications. Neuropsychopharmacology 2006;31:2318-2325.
26. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean? Schizophr Res 2005;79:231-238.
27. Green AI, Tohen MF, Hamer RM et al. First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophr Res 2004;66:125-135.
28. Kinon BJ, Chen L, Ascher-Svanum H et al. Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophr Res 2008;102:230-240.
29. ® 9.3. Cary, NC, USA: SAS Institute Inc., 2011.
30. R Core TEAM. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing, 2012.
31. Hosmer DW, Lemeshow S. Applied Logistic Regression. In: Cressie N, Fisher N, Johnstone I, Kadane J, Scott D, Silverman B, Smith A, Teugels J, eds. Wiley Series in Probability and Mathematical Statistics, 2nd edn. Chichester: John Wiley & Sons, 2000: 92-99.
32. Agid O, Kapur S, Arenovich T, Zipursky RB. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry 2003;60:1228-1235.
33. Correll CU, Malhotra AK, Kaushik S, McMeniman M, Kane JM. Early prediction of antipsychotic response in schizophrenia. Am J Psychiatry 2003;160:2063-2065.
34. Kinon BJ, Chen L, Ascher-Svanum H et al. Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacology 2010;35:581-590.
35. Schennach R, Riesbeck M, Mayr A et al. Should early improvement be re-defined to better predict the maintenance of response in first-episode schizophrenia patients? Acta Psychiatr Scand 2012 [Epub ahead of print].
36. Haro JM, Edgell ET, Novick D et al. Effectiveness of antipsychotic treatment for schizophrenia: 6-month results of the Pan-European Schizophrenia Outpatient Health Outcomes (SOHO) study. Acta Psychiatr Scand 2005;111:220-231.
37. Verma S, Subramaniam M, Abdin E, Poon LY, Chong SA. Symptomatic and functional remission in patients with first-episode psychosis. Acta Psychiatr Scand 2012;126:282-289.
38. Shrivastava A, Shah N, Johnston M, Stitt L, Thakar M. Predictors of long-term outcome of first-episode schizophrenia: a ten-year follow-up study. Indian J Psychiatry 2010;52:320-326.
39. Reynolds GP. The pharmacogenetics of symptom response to antipsychotic drugs. Psychiatry Investig 2012;9:1-7.
40. Lewis SW, Tarrier N, Drake RJ. Integrating non-drug treatments in early schizophrenia. Br J Psychiatry Suppl 2005;48:s65-s71.
41. Agid O, Arenovich T, Sajeev G et al. An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. J Clin Psychiatry 2011;72:1439-1444.
42. Silvestri S, Seeman MV, Negrete JC et al. Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacology 2000;152:174-180.
43. Singh SP, Croudace T, Amin S et al. Three-year outcome of first-episode psychoses in an established community psychiatric service. Br J Psychiatry 2000;176:210-216.
44. Gasquet I, Haro JM, Tcherny-Lessenot S, Chartier F, Lepine JP. Remission in the outpatient care of schizophrenia: 3-year results from the Schizophrenia Outpatients Health Outcomes (SOHO) study in France. Eur Psychiatry 2008;23:491-496.
45. Marshall M, Lewis S, Lockwood A, Drake RJ, Jones P, Croudace T. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients. Arch Gen Psychiatry 2005;62:975-983.
46. Perkins DO, Gu H, Boteva K, Lieberman JA. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry 2005;162:1785-1804.
47. Hides L, Dawe S, Kavanagh DJ, Young RM. Psychotic symptom and cannabis relapse in recent-onset psychosis. Prospective study. Br J Psychiatry 2006;189:137-143.
48. Gonzalez-Pinto A, Alberich S, Barbeito S et al. Cannabis and first-episode psychosis: different long-term outcomes depending on continued or discontinued use. Schizophr Bull 2011;37:631-639.